GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

AstraZeneca AZN.L · GBp

Health Care · Pharmaceuticals · LSE · 🇬🇧 United Kingdom

FTSE 100

Compare

14,066.00p

+0.98%

Close of 9 Nov 2026, in pence

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$58.74bn

FY2016FY2025

Net income

$10.22bn

FY2016FY2025

Free cash flow

$8.67bn

FY2016FY2025

Shareholders' equity

$48.67bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$58.74bn$52.94bn$46.58bn$44.25bn$37.11bn$29.27bn$24.50bn$20.99bn$23.45bn$20.92bn
Gross profit$48.11bn$39.70bn$34.45bn$28.04bn$22.60bn$21.66bn$17.73bn$15.06bn$17.38bn$15.86bn
Research and development$14.23bn$11.96bn$10.52bn$9.62bn$8.38bn$6.46bn$5.35bn$5.00bn$5.65bn$5.12bn
Operating income$13.74bn$9.90bn$9.57bn$5.05bn$2.81bn$4.97bn$2.82bn$2.97bn$3.62bn$3.24bn
Net income$10.22bn$6.89bn$6.06bn$3.28bn$109.9m$3.39bn$1.34bn$2.05bn$3.13bn$3.18bn
Diluted earnings per share6.544.413.882.100.072.581.021.622.472.51

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$114.07bn$104.03bn$101.12bn$96.48bn$105.36bn$66.73bn$61.38bn$60.65bn$63.35bn$62.53bn
Cash and short-term investments$5.74bn$5.65bn$5.91bn$6.24bn$6.37bn$7.95bn$6.22bn$5.59bn$4.55bn$5.81bn
Total liabilities$65.36bn$63.16bn$61.95bn$59.42bn$66.08bn$51.09bn$46.78bn$46.61bn$46.71bn$45.86bn
Debt$29.62bn$30.30bn$28.62bn$29.23bn$30.78bn$20.38bn$18.23bn$19.11bn$17.81bn$16.81bn
Shareholders' equity$48.67bn$40.79bn$39.14bn$37.04bn$39.27bn$15.62bn$13.13bn$12.47bn$14.96bn$14.85bn
Shares outstanding1,563m1,562m1,561m1,559m1,547m1,313m1,312m1,267m1,267m1,266m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations$14.57bn$11.86bn$10.35bn$9.81bn$5.96bn$4.80bn$2.97bn$2.62bn$3.58bn$4.14bn
Capital spending−$5.91bn−$4.59bn−$3.78bn−$2.57bn−$2.20bn−$2.61bn−$2.46bn−$1.37bn−$1.62bn−$2.31bn
Free cash flow$8.67bn$7.28bn$6.57bn$7.24bn$3.76bn$2.19bn$509.0m$1.25bn$1.96bn$1.83bn
Dividends paid−$4.97bn−$4.63bn−$4.48bn−$4.36bn−$3.86bn−$3.57bn−$3.59bn−$3.48bn−$3.52bn−$3.56bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue$15.29bn$15.29bn$15.50bn$15.19bn$14.84bn$13.96bn$14.54bn$13.96bn
Gross profit$11.25bn$12.61bn$12.38bn$12.33bn$11.16bn$10.67bn$9.85bn$9.93bn
Operating income$3.09bn$4.25bn$2.98bn$3.58bn$3.51bn$3.78bn$1.99bn$2.87bn
Net income$2.49bn$3.08bn$2.33bn$2.53bn$2.52bn$3.00bn$1.46bn$1.47bn
Diluted earnings per share1.601.971.491.621.611.920.940.94
Cash from operations$2.90bn$3.36bn$2.34bn$5.13bn$3.39bn$3.71bn$2.91bn$3.38bn
Capital spending−$757.0m−$1.54bn−$1.29bn−$1.73bn−$1.92bn−$969.0m−$955.0m−$1.36bn
Free cash flow$2.15bn$1.82bn$1.05bn$3.41bn$1.46bn$2.74bn$1.95bn$2.02bn
Total assets$116.43bn$114.02bn$114.07bn$114.46bn$112.42bn$106.25bn$104.03bn$104.92bn
Cash and short-term investments$4.99bn$7.67bn$5.74bn$8.18bn$7.11bn$5.41bn$5.65bn$4.92bn
Debt$29.95bn$32.41bn$28.20bn$31.25bn$31.57bn$3.41bn$29.00bn$30.46bn
Shareholders' equity$50.56bn$47.33bn$48.67bn$45.89bn$44.72bn$41.04bn$40.79bn$40.72bn

Growth per year

Compound annual rate

3 years5 years10 years
Revenue9.9%14.9%9.4%
Operating income39.6%22.6%14.8%
Net income46.1%24.7%14.1%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin78.6%74.2%72.4%72.8%
Operating margin21.2%18.9%17.1%16.2%
Net margin15.3%13.1%11.1%11.1%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings28.231.836.671.6—38.199.748.627.823.6
Price to sales4.94.14.85.34.84.45.54.83.73.6

Dividends and splits

Per share, in the currency the company pays

Paid for 33 years. Last went ex-dividend on 6 Aug 2026.

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Paid in the year2.6664.5372.3362.3462.2170.6481.3742.16
  • 1.015-for-1 split · 1 Jun 1993

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.